Aldi Recall Alert: Hidden Allergens in Two Products Sold in 16 States
If you've shopped at Aldi recently, it might be time to double-check your freezer. The budget grocery giant has issued two new food recalls affecting 16 states. The recall comes after potential allergen risks were discovered in products sold under its private label brands.
The first recall involves Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. According to the U.S. Food and Drug Administration, the product may contain undeclared milk, a major allergen.
The affected churro bites come in 7.05-ounce cardboard boxes marked with UPC Code 4061459561807 and a "Best If Used By" date of July 14, 2026. While no illnesses have been reported, customers with milk allergies are advised not to consume the product and instead return it to Aldi for a full refund.
This product was distributed in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee.
The second recall affects Atlantic Salmon Portions with Seafood Stuffing, manufactured by Santa Monica Seafood. This item was sold in 16-ounce packages with UPC Code 4061459716313 and a use/freeze-by date of June 2, 2025. It was distributed to Aldi locations in California, Nevada, and Arizona. The product may contain undeclared soy, another top allergen that can cause serious reactions for sensitive individuals.
For customers with food allergies, these undeclared ingredients pose a serious health risk. Dr. Sebastian Lighvani, a New York-based allergist, explained to Newsweek that even trace amounts of allergens like milk or soy can trigger immune responses in susceptible individuals. They could lead to potentially life-threatening reactions.
Aldi emphasized its commitment to consumer safety in a statement, directing concerned customers to their recall page and offering full refunds on returned products.
Whether you have known allergies or not, it's worth taking a moment to check your fridge and freezer. Recalls like these are a reminder of how vital food labeling and consumer awareness are, especially when it comes to the ingredients we can't see.
Aldi Recall Alert: Hidden Allergens in Two Products Sold in 16 States first appeared on Men's Journal on Jun 11, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Nearly 45,000 Pounds of Shrimp Recalled for Potentially 'Fatal' Listeria Contamination
A seafood brand is recalling a shrimp product for possible listeria contamination Listeria can cause "serious and sometimes fatal infections" in at-risk individuals, pregnancy complications and short-term, serious symptoms for healthy people Bornstein Seafoods discovered the issue in a routine sampling and is presently determining the root causeA seafood brand is issuing a recall of some of its shrimp products. According to a statement issued by the U.S. Food and Drug Administration, Bornstein Seafoods Inc. is recalling 44,550 lbs. of its Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat due to a possible contamination of listeria. Listeria monocyogenes is a foodborne illness that can cause "serious and sometimes fatal infections" in small children, elderly people or otherwise at-risk individuals, as well as cause pregnancy complications, the statement reads. Healthy people can still experience short-term symptoms like fever, intense headache, stiffness, nausea, abdominal pain and diarrhea. Bornstein Seafoods came across the possible contamination during a routine sampling, has stopped the product distribution and is presently investigating the root cause. As of publication time, no illnesses have been reported, per the FDA. The shrimp products were sold directly to distributors and retailers in the Pacific Northwest, including in California, Oregon, Washington and British Columbia in Canada, though "products may have been further distributed and sold at retailers nationwide." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. The recall extends to multiple products, including Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat in 1 lb. or 5 lb. plastic bags. The complete list of the recalled products' descriptions and lot codes are as follows: Fzn Shrimp Meat 250/350 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19008 Fzn Shrimp Meat 250/350 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A19009 Fzn Shrimp Meat 250/350 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, P11710 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19009 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19019 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19026 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19030 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19032 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19037 Fzn Shrimp Meat 350/500 Ct 15 X 1 Lb Bag Bsi Msc: 614133200246, A19039 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A18989 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A19006 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, A19007 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, P11709 Fzn Shrimp Meat 350/500 Ct 4 X 5 Lb Bag Bsi Msc: 614133200239, P11710 Those who bought any of the recalled products should return the item to the seller for a full refund. Any questions regarding the recall should be directed to Andrew@ Read the original article on People
Yahoo
an hour ago
- Yahoo
Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions
SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab (registered as Niktimvo® in the United States) and retifanlimab (registered as Zynyz® in the U.S. and European Union) added to the current partnered portfolio of Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib). Under the terms of the expanded agreement, Incyte will be responsible for the development, manufacture and supply of both axatilimab and retifanlimab to the region, while ST will have responsibility for regulatory, distribution and local marketing and medical affairs related activities. ST Chief Executive Officer, Mr Carlo Montagner, welcomed the expansion of the partnership agreement with Incyte, a leading global biopharmaceutical company, and the opportunity to bring these important medicines to eligible patients in the local region. "Specialised Therapeutics has partnered with Incyte since 2021 and we are delighted to be extending this successful partnership," he said. "As part of our initial agreement, our teams have worked collaboratively to commercialise Minjuvi, which has been approved for use in Australia, and Pemazyre, which has been approved in Australia and Singapore, and we look forward to expanding the portfolio to help more patients with rare and hard-to-treat conditions." "The addition of axatilimab and retifanlimab to the partnership agreement with Incyte recognises our strong track record of working with local stakeholders to bring innovative medicines to patients where unmet medical needs persist, despite the availability of existing treatments," said Mr Montagner. "Our focus will be on seeking regulatory and reimbursement approval for all four medicines in the region, to ensure equitable access to these treatments are available for patients as soon as practicable." ST anticipates submitting axatilimab and retifanlimab for local regulatory and reimbursement approval in 2025. Incyte CEO, Mr Hervé Hoppenot said the expanded partnership agreement reflected the synergies between the two companies, with a shared goal of improving outcomes for patients with unmet medical needs. "We are pleased to extend our partnership with ST to include axatilimab and retifanlimab," he said. "ST has already demonstrated its ability to navigate complex regional regulatory pathways for Minjuvi and Pemazyre, and we look forward to continuing our work together to make these new therapies available for the oncology community in the Asia-Pacific region." Axatilimab is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody. It was approved by the US Food and Drug Administration (FDA) in August 2024 as a treatment for adults and children with chronic graft-versus-host disease (GVHD) who have received at least two prior treatments (systemic therapy) and require additional treatment.1 Chronic GVHD usually occurs 3 months after a transplant - typically haematopoietic stem cell or bone marrow transplantation, but occasionally also solid organ transplants - where the donor cells ("graft") attack the graft recipient's cells ("host").2 Chronic GVHD can affect all organs, but commonly impacts the skin, mouth, eyes, lungs, stomach, bowel, and liver.2,3 The Phase II clinical trial for axatilimab involved 79 patients from 13 countries, including Australia and Singapore.4 Retifanlimab is an intravenous immune checkpoint (PD-1) inhibitor that has been approved in the US in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy.5 Retifanlimab is also approved in the US6 and Europe7 for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). MCC is a rare and aggressive type of skin cancer, that is often difficult to diagnose due to the lack of specific features to distinguish it from other common skin cancers.8 Australia has the highest incidence of MCC in the world.9 The pivotal Phase II clinical trial of retifanlimab in MCC enrolled 101 chemotherapy-naïve patients from 12 countries, including Australia.10 In addition to MCC, retifanlimab, in combination with chemotherapy, is currently being investigated as a potential therapeutic option in other hard-to-treat cancers, including metastatic non-small cell lung cancer (NSCLC). Ends. About Specialised Therapeutics Founded in 2007, Specialised Therapeutics is the region's largest independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA). Additional information can be found at About axatilimab (Niktimvo®) Axatilimab-csfr (registered as Niktimvo® in the United States) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the US for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least 40 kg (88.2 lbs). In 2016, Syndax licensed exclusive worldwide rights to develop and commercialise axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialisation license agreement for axatilimab in chronic GVHD and any future indications. Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). Niktimvo is a trademark of other trademarks are the property of their respective owners. About retifanlimab (Zynyz®) Retifanlimab-dlwr (registered as Zynyz® in the United States and European Union) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S. Zynyz is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the US. This indication is approved under accelerated approval based on tumour response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Zynyz is marketed by Incyte in the US. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. Zynyz is a registered trademark of Incyte. References: US FDA. FDA approves axatilimab-csfr for chronic graft-versus-host disease, 14 Aug 2024. Available at: drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease [Accessed Mar 2025]. The Australasian College of Dermatologists. A-Z of Skin: Graft Versus Host Disease, Nov 2020. Available at: [Accessed Mar 2025]. Leukaemia Foundation Australia. Factsheet: Graft versus host disease, 24 May 2024. Available at: [Accessed Mar 2025]. A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201); NCT04710576. Available at: [Accessed Mar 2025]. FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. [Accessed May 2025] US FDA. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma, 22 Mar 2023. Available at: [Accessed Mar 2025]. European Medicines Agency (EMA). Zynyz (retifanlimab): Marketing Authorisation in the European Union (EU), 19 Apr 2024. Available at: [Accessed Mar 2025]. NeuroEndocrine Cancer Australia. Merkel Cell Carcinoma: The Facts, 19 Nov 2023. Available at: [Accessed Mar 2025]. The Australasian College of Dermatologists. A-Z of Skin: Merkel cell carcinoma, Oct 2024. Available at: atoz/merkel-cell-carcinoma/ [Accessed Mar 2025]. Grignani G, et al. Updated Results From POD1UM-201: A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma. Presented at the European Society for Medical Oncology Congress 2023, Madrid, Spain; 20-24 October 2023. View original content to download multimedia: SOURCE Specialised Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Scientists develop breath test to ID people and check health
Breathing into a bag or tube usually means you've been pulled over by police who want to check for drinking and driving can lead to the loss of a driving licence or even imprisonment. But a team of scientists have found every breath you take to be like a fingerprint that discloses who you are with 97% accuracy and can be assessed for "insights" into physical and even mental health. "You would think that breathing has been measured and analyzed in every way," said Noam Sobel, one of a team of researchers based at the Weizmann Institute of Science near Tel Aviv who said they "stumbled upon a completely new way to look at respiration" they describe as "a brain readout." The researchers tracked breathing in 100 "healthy young adults" over 24 hours using a "lightweight wearable device" they made and found that the "high-level accuracy" of the tests "remained consistent across multiple retests conducted over a two-year period." Most breathing tests last less than half an hour, meaning such "brief snapshots" cannot assess "subtle patterns," according to the team, which had its findings published in the Cell Press journal Current Biology. "I thought it would be really hard to identify someone because everyone is doing different things, like running, studying, or resting," said researcher Timna Soroka. But according to the team, the breathing test rivals "the precision of some voice recognition technologies." "It turns out their breathing patterns were remarkably distinct," Soroka said, following the longer-than-usual test, which not only could identify people but provide signals related to health. The Israel-based team said that the tests showed breathing to be "correlated with a person's body mass index, sleep-wake cycle, levels of depression and anxiety, and even behavioural traits." "For example, participants who scored relatively higher on anxiety questionnaires had shorter inhales and more variability in the pauses between breaths during sleep," the researchers reported. The team's laboratory's prior investigations of olfaction in animals got them thinking that since mammals' brains process odour information during inhalation, there could be some value in testing whether there people have a unique breathing pattern in the same way each brain is unique. The findings follow the development over the past decade of gadgets that can identify people by how they walk, with so-called gait recognition technology used by police in China in street cameras since at least 2018. It all means that with every breath you take and every move you make, they might some day be watching - and identifying - you.
